8-K: Carisma Terminates Merger, Buys Out Moderna Deal

Carisma Therapeutics Inc. terminated its merger agreement with OrthoCellix due to failed financing and amended its collaboration with Moderna for a one-time payment.

Summary

• Carisma Therapeutics Inc. (CARM) terminated its Agreement and Plan of Merger with OrthoCellix, Inc. and Ocugen, Inc., effective September 16, 2025.
• The termination was a direct result of OrthoCellix's failure to secure $25.0 million in concurrent financing commitments by the September 15, 2025 deadline.
• Carisma is entitled to a $750,000 termination fee and a $500,000 expense reimbursement from OrthoCellix, totaling $1.25 million, payable by September 18, 2025.
• OrthoCellix has not confirmed its intention to pay these fees, and Carisma intends to vigorously enforce its right to receive payment.
• Carisma also amended its Collaboration and License Agreement with ModernaTX, Inc. on September 16, 2025.
• Under the amendment, Moderna will pay Carisma a one-time cash payment of $4.0 million within ten business days.
• In exchange for this payment, Moderna is relieved of all future financial obligations, including development, regulatory, and commercial milestone payments, royalties on net sales, and research costs; its licenses became fully paid-up, perpetual, irrevocable, and royalty-free.
• The company faces significant challenges in identifying and completing an alternative strategic transaction before October 7, 2025, which is the deadline for Nasdaq continued listing compliance.
• If no alternative transaction is completed, Carisma expects to pursue an orderly wind-down of operations, with an explicit warning that it is unlikely there will be a meaningful amount of cash available for distribution to stockholders.

Sentiment

Score: 2

Explanation: The filing indicates severe financial distress and a high probability of liquidation with minimal shareholder recovery. The termination of a key merger, coupled with an imminent delisting threat and explicit warnings about shareholder value in a wind-down, points to a very negative outlook. The Moderna payment provides some immediate cash but at the cost of future upside, and even the termination fees are uncertain.

Positives

• Secured a one-time cash payment of $4.0 million from Moderna, providing immediate liquidity.
• Entitled to a $750,000 termination fee and $500,000 expense reimbursement (total $1.25 million) from OrthoCellix, though payment is not yet confirmed.
• Preservation of existing cash resources by terminating the merger, avoiding further costs associated with a potentially unconsummated transaction.

Negatives

• Termination of the merger agreement with OrthoCellix, indicating a failure to execute a critical strategic transaction and secure necessary financing.
• Loss of potential future milestone payments and royalties from the Moderna collaboration, as these were bought out for a fixed, immediate sum.
• OrthoCellix has not confirmed payment of the $1.25 million in termination fees and expense reimbursements, creating uncertainty regarding this expected cash inflow.
• Significant risk of delisting from The Nasdaq Stock Market LLC by October 7, 2025, if an alternative strategic transaction is not completed.
• High likelihood of an orderly wind-down of operations if no strategic transaction is found, with an explicit statement that it is 'unlikely' there will be meaningful cash distribution to stockholders.
• The company may be forced to commence bankruptcy or liquidation proceedings.

Risks

• Inability to identify, evaluate, and complete an alternative strategic transaction on an expedited basis before October 7, 2025.
• Potential delisting of common stock from The Nasdaq Stock Market LLC prior to or on October 7, 2025, due to noncompliance with listing standards.
• Uncertainty regarding the receipt of the $1.25 million termination fee and expense reimbursement from OrthoCellix.
• Inability to preserve existing cash resources sufficiently to maintain operations or execute a strategic plan.
• Inability to continue as a going concern.
• Challenges in executing a planned orderly wind-down of operations effectively.
• Unlikely prospect of meaningful cash available for distribution to stockholders in connection with a wind-down of operations or a dissolution and liquidation.
• Potential for litigation or other claims related to a liquidation and dissolution of the company.
• Inability to identify and complete additional asset monetization transactions.

Future Outlook

Carisma Therapeutics expects to continue pursuing asset monetization transactions and evaluating potential alternative strategic transactions. However, it faces significant challenges in completing such a transaction before October 7, 2025, the Nasdaq delisting deadline. If no alternative is found, the company anticipates an orderly wind-down of operations, with an explicit warning that it is unlikely there will be meaningful cash available for distribution to stockholders. The board of directors may elect to commence bankruptcy or liquidation and dissolution proceedings.

Management Comments

• "The Company intends to vigorously seek to enforce its right to receive payment [of the termination fee and expense reimbursement]."
• "It will be extremely challenging for the Company to identify, evaluate and complete an alternative strategic transaction before October 7, 2025, beyond which date the Nasdaq Hearings Panel does not have discretion to grant the Company continued listing for noncompliance with Nasdaq listing standards."
• "If the Company does not identify and complete an alternative strategic transaction on an expedited basis, the Company expects to pursue an orderly wind down of its remaining operations."
• "It is unlikely that there will be a meaningful amount of cash available for distribution to stockholders in connection with a wind down of the Company's operations or a dissolution and liquidation of the Company."

Industry Context

NA

Legal Proceedings

• The company intends to vigorously seek to enforce its right to receive the $750,000 termination fee and $500,000 expense reimbursement from OrthoCellix, which could lead to legal action if not paid.
• The company may be subject to litigation or other claims related to a liquidation and dissolution of the company.

Stakeholder Impact

• Shareholders: Highly negative impact. Unlikely to receive meaningful cash distribution in a wind-down scenario. Significant risk of delisting and potential loss of investment.
• Employees: Potential for job losses and uncertainty regarding future employment if operations are wound down.
• Creditors: Company is required under Delaware law to pay outstanding obligations and make reasonable provision for contingent and unknown obligations prior to any distributions to stockholders, indicating creditors would be prioritized over shareholders in a liquidation.

Next Steps

• Receive $4.0 million cash payment from Moderna within ten business days following September 16, 2025.
• Vigorously seek to enforce the right to receive $1.25 million in termination fees and expense reimbursements from OrthoCellix by September 18, 2025.
• Continue to attempt to sell or otherwise dispose of or monetize remaining assets.
• Evaluate potential alternative strategic transactions.
• Identify and complete an alternative strategic transaction before October 7, 2025, to avoid Nasdaq delisting.
• If no alternative strategic transaction is completed, pursue an orderly wind-down of operations.
• Potentially commence bankruptcy or liquidation and dissolution proceedings, subject to board and stockholder approval.

Key Dates

Recommendation

The company faces imminent delisting from Nasdaq by October 7, 2025, and explicitly states that a wind-down of operations is likely to result in no meaningful cash distribution to stockholders. The termination of a critical merger and the buyout of future Moderna royalties for a relatively small, immediate cash injection underscore severe financial distress and a lack of viable long-term prospects. The uncertainty surrounding the collection of termination fees further exacerbates the negative outlook. Investors should consider exiting their positions to avoid further capital loss.

Keywords

Carisma Therapeutics, CARM, SEC Filing, 8-K, Merger Termination, Moderna Agreement, Collaboration Amendment, Nasdaq Delisting, Wind-down, Liquidation, Asset Monetization, Biotechnology, Pharmaceutical